VivoSeq
Other

Pembrolizumab

0

Pipeline Programs↗

70

Active Trials↗

35

Companies Involved↗

Pembrolizumab is an early-stage landscape with 0 programs across 35 companies. The most active players are Merck & Co., Eisai, Leap Therapeutics, Inc..

Intelligence

Pipeline Metrics

Competitive Density

54/100

Pipeline Velocity

34/100

Mech. Concentration

N/A

Completion Rate

66/100

Attrition Rate

19/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Merck & Co. logo

Merck & Co.

0 programs

PreclinicalEisai logo

Eisai

0 programs

PreclinicalL

Leap Therapeutics, Inc.

0 programs

PreclinicalSanofi logo

Sanofi

0 programs

PreclinicalE

Eikon Therapeutics

0 programs

PreclinicalAmgen logo

Amgen

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

184

clinical trials

Completed69 · 38%
Recruiting36 · 20%
Terminated29 · 16%
Active, not recruiting25 · 14%
Not yet recruiting9 · 5%
Unknown status9 · 5%
Other7 · 4%

Clinical Trials

Trial Activity

184 trials

Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC
Recruiting·UUNICANCER·Phase 2·NCT06078384·354 enrolled
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
Recruiting·—·Phase 2·NCT04468061·110 enrolled
Phase II Study of Moderate-dose Hypofractionated RT Combined With Pembrolizumab for HCC With Diffuse Tumor Thrombosis
Recruiting·—·Phase 2·NCT06389422·30 enrolled
Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK
Recruiting·HHunan Province Tumor Hospital·Phase 2·NCT05266846·78 enrolled
Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer
Recruiting·—·Phase 2·NCT06493019·23 enrolled
Phase 1 Study Evaluating Safety and Tolerability of SL-T10, GX-I7, and Pembrolizumab Triple Combination in mCRPC.
Recruiting·SSL VAXiGEN·Phase 1·NCT06344715·78 enrolled
POTENT - Tepotinib in Combination With Pembrolizumab in NSCLC
Recruiting·IInstitute of Cancer Research, United Kingdom·Phase 1·NCT05782361·19 enrolled
Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin
Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT06576037·128 enrolled
Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC
Recruiting·—·Phase 2·NCT06052839·15 enrolled
Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients
Recruiting·PProvidence Health & Services·Phase 2·NCT06353997·12 enrolled
Palbociclib and Pembrolizumab in Sarcoma
Recruiting·—·Phase 1·NCT06113809·8 enrolled
NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)
Recruiting·WWest German Study Group·Phase 3·NCT06081244·348 enrolled
A Feasibility Window Study of Pembrolizumab Prior to Second Evacuation for Post-molar Gestational Trophoblastic Neoplasia
Recruiting·IImperial College London·Phase 2·NCT05635344·20 enrolled
A Study of Pembrolizumab in People With Ultra-Rare Sarcomas
Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT07089992·32 enrolled
Axitinib +/- Pembrolizumab in First Line Treatment of mPRCC
Recruiting·CCentre Leon Berard·Phase 2·NCT05096390·72 enrolled
Page 1 of 13

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)